Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety/secondary-exposure counseling claims are supported by the provided label excerpts (handwashing, avoiding contact with unwashed/unclothed sites, risk of transfer causing virilization in children/women). However, multiple efficacy/indication and administration details are not supported by the supplied label text, and the claim about avoiding showering/swimming for at least two hours is not present in the provided label excerpts.
Category Scores
Accurate Statements
Hands should be washed thoroughly after application of AndroGel.
2 DOSAGE AND ADMINISTRATION — 2.2: “Patients should wash hands with soap and water immediately after application.”
There is a risk of transferring AndroGel to others through skin-to-skin contact.
5.1: “The risk of transfer was increased…” and “Children and women should avoid contact with unwashed or unclothed application sites…”
Transferred AndroGel can cause unwanted sexual development or hair growth in children and women.
5.1: secondary exposure signs/symptoms in children; and adult women virilization signs (including body hair distribution changes). 17.2: in children unexpected sexual development; in women “changes in hair distribution, increase in acne, or other signs of testosterone effects.”
Transferred AndroGel can cause acne and increased body or facial hair in women.
17.2: “In women: changes in hair distribution, increase in acne, or other signs of testosterone effects.” 5.1 also notes adult women virilization signs including “changes in body hair distribution” and “significant increase in acne.”
There is a risk of transferring AndroGel to others through skin-to-skin contact.
2.2: precautions to minimize secondary exposure from topical gel and wash application site(s) prior to anticipated skin-to-skin contact.
There is a risk of transferring AndroGel to others through skin-to-skin contact.
6.2: “In some of the cases, direct contact with the sites of application… was reported.”
There is a risk of transferring AndroGel to others through skin-to-skin contact.
5.1: “Children and women should avoid contact with unwashed or unclothed application sites…”
Unsupported Statements
AndroGel is a prescription medication used to treat low testosterone levels in men.
The provided label excerpts do not include indication language for low testosterone/hypogonadism treatment.
AndroGel is indicated for testosterone replacement therapy (TRT) in adult males diagnosed with hypogonadism.
The provided label excerpts do not include the approved indication section.
Hypogonadism is characterized by deficient testosterone production.
The provided label excerpts do not define hypogonadism.
The gel is typically applied once daily to the shoulders and upper arms.
The provided label excerpts do not state dosing frequency or specific application sites (shoulders/upper arms).
After applying AndroGel, showering or swimming should be avoided for at least two hours to prevent transfer to others.
No “two hours” or showering/swimming timing is stated in the provided label excerpts (only precautions about washing, covering, and avoiding contact with unwashed/unclothed sites).
Common side effects of AndroGel can include increased blood pressure.
The provided label excerpts do not list increased blood pressure as a side effect.
Common side effects of AndroGel can include prostate problems.
The provided label excerpts do not list prostate problems as a side effect.
Common side effects of AndroGel can include skin irritation at the application site.
The provided label excerpts do not list skin irritation at the application site as a common side effect.
AndroGel is a prescription medication and must be obtained from a licensed pharmacy upon presentation of a valid prescription.
The provided label excerpts do not address how the medication must be dispensed or obtained.
AndroGel is not available for direct purchase by consumers without a prescription.
The provided label excerpts do not address consumer purchase/dispensing policy.
Contradictions
Important Omissions
Strict precautions specific to preventing secondary exposure beyond handwashing—e.g., covering application sites with clothing after gel has dried, washing the application site thoroughly with soap and water prior to anticipated skin-to-skin contact, and washing the other person’s contact area if contact occurs with unwashed/unclothed sites.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes several supported secondary-exposure warnings (handwashing and minimizing contact with unwashed/unclothed sites implied by transfer risk), but it also includes at least one unsupported specific behavioral instruction (“avoid showering/swimming for at least two hours”) and omits other key label-listed precautions in the provided excerpts (cover application site with clothing after drying; wash application site before anticipated contact; wash other person’s contact area).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided prescribing-information excerpts, especially the indication/TRT statements and the “avoid showering/swimming for at least two hours” instruction.
Suggested Improvement
Limit claims to what is supported by the provided label sections for secondary exposure (5.1, 2.2, 6.2, 17.2). Replace the unsupported “two hours” shower/swimming timing with the label-supported precautions: wash hands immediately, cover application sites after gel dries, wash application site before anticipated skin-to-skin contact, and wash the other person’s contact area as soon as possible if contact occurs with unwashed/unclothed sites.